Work

What Is the Most Cost-effective Strategy for Treating Chronic Myeloid Leukemia After Imatinib Loses Patent Exclusivity in the United States?

Year: 2014

Type: article

Source: The 36th Annual Meeting of the Society for Medical Decision Making

Author: William V. Padula

Language: English

Topic: Health Systems, Economic Evaluations, Quality of Life

Subfield: Economics and Econometrics

Field: Economics, Econometrics and Finance

Domain: Social Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2346343155

FWCI:

Cites:

Cited by:

Related to: 10